Lupin Limited has informed the Exchange regarding a press release dated April 07, 2026, titled "Lupin Announces the Approval of Dapagliflozin Tablets in the United States".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin Limited has received approval from the U.S. FDA for its Abbreviated New Drug Application for Dapagliflozin Tablets in 5 mg and 10 mg dosages. The approved product is bioequivalent to Farxiga, which is AstraZeneca's brand-name medication. Dapagliflozin is used for diabetes treatment indications. This approval allows Lupin to launch a generic version of this widely-used medication in the United States market, which is a significant milestone for the company's US portfolio expansion.
This FDA approval is positive for Lupin as it enables the company to enter the US market with a generic version of a popular diabetes drug, potentially creating a new revenue stream and strengthening Lupin's position in the US pharmaceutical market.